The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | S | Sensory organs | |
2 | S01 | Ophthalmologicals | |
3 | S01E | Antiglaucoma preparations and miotics | |
4 | S01ED | Beta blocking agents |
Code | Title | |
---|---|---|
S01ED01 | Timolol | |
S01ED02 | Betaxolol | |
S01ED03 | Levobunolol | |
S01ED04 | Metipranolol | |
S01ED05 | Carteolol | |
S01ED06 | Befunolol | |
S01ED51 | Timolol, combinations | |
S01ED52 | Betaxolol, combinations | |
S01ED54 | Metipranolol, combinations | |
S01ED55 | Carteolol, combinations |
Active Ingredient | Description | |
---|---|---|
Befunolol |
|
|
Betaxolol |
Betaxolol is a cardioselective Beta1 receptor blocker which, when applied topically to the eye, lowers intraocular pressure. It is thought to produce this effect by reducing the rate of production of aqueous humour. |
|
Carteolol |
Carteolol is a non-selective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity (ISA) and without significant membrane stabilizing activity. Carteolol reduces normal and elevated intraocular pressure whether or not accompanied by glaucoma. |
|
Levobunolol |
Levobunolol is a non-cardioselective beta-adrenoceptor blocking agent, equipotent at both beta1 and beta2 receptors. The primary mechanism of action of levobunolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. Levobunolol reduces intraocular pressure with little or no effect on pupil size in contrast to the miosis which cholinergic agents are known to produce. |
|
Metipranolol |
|
|
Nipradilol |
|
|
Timolol |
Timolol is a non-selective beta-adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anaesthetic activity. Timolol reduces intra-ocular pressure, whether or not this is associated with glaucoma. |
Title | Information Source | Document Type | |
---|---|---|---|
BETAGAN Eye drops, solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
Betoptic Eye Drops Solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
BETOPTIC Eye drops, suspension | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
COMBIGAN Eye drops, solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
COSOPT Eye drops, solution | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
TIMOPTIC Ophthalmic solution | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
TIMOPTOL Eye drops, solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
TIOPEX Eye gel | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |